AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Symbicort Maintenance and Reliever Therapy - Experience in Real Life Setting in Malaysia
Phase 4
Completed
- Conditions
- Asthma
- First Posted Date
- 2007-12-19
- Last Posted Date
- 2010-12-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 201
- Registration Number
- NCT00576316
- Locations
- 🇲🇾
Research Site, Kuala Lumpur, Malaysia
52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period
Phase 3
Completed
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2007-12-18
- Last Posted Date
- 2012-03-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 891
- Registration Number
- NCT00575588
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Evaluation of the Efficacy of Rosuvastatin in Daily Practice in Untreated High Risk Patients (CHALLENGE)
Completed
- Conditions
- HypercholesterolemiaPeripheral Vascular DiseaseCVADiabetesCoronary Heart Disease
- First Posted Date
- 2007-12-17
- Last Posted Date
- 2007-12-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2660
- Registration Number
- NCT00574782
Efficacy and Safety Study of D9421-C 9 mg and 15 mg Versus Placebo in Japanese Patients With Active Crohn's Disease
Phase 2
Completed
- Conditions
- Crohn's Disease
- Interventions
- Drug: D9421-C, 9mgDrug: D9421-C, 15mgDrug: Placebo
- First Posted Date
- 2007-12-14
- Last Posted Date
- 2012-07-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 75
- Registration Number
- NCT00573469
- Locations
- 🇯🇵
Research Site, Toyama, Japan
ARIA (Atacand Renoprotection In NephropAthy Pt.)
Phase 4
Completed
- Conditions
- Non-diabetic Nephropathy With Hypertension
- Interventions
- First Posted Date
- 2007-12-14
- Last Posted Date
- 2011-08-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 128
- Registration Number
- NCT00573430
- Locations
- 🇰🇷
Research Site, Seoul, Korea, Republic of
Efficacy Observational Study of Candesartan Cilexetil on Hypertensive Patients
Completed
- Conditions
- Primary Hypertension
- First Posted Date
- 2007-12-14
- Last Posted Date
- 2010-08-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1940
- Registration Number
- NCT00573742
- Locations
- 🇷🇴
Research Site, Timisoara, Romania
Non-interventional Surveillance of Effectiveness of Symbicort® Maintenance And Reliever Therapy (Symbicort® SMART) in the Treatment of Moderate and Severe Asthma
Completed
- Conditions
- Asthma
- First Posted Date
- 2007-12-14
- Last Posted Date
- 2010-12-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 330
- Registration Number
- NCT00573222
- Locations
- 🇭🇷
Research Site, Zagreb, Croatia
🇭🇷Croatia, Zadar, Croatia
Open Label, Dose Escalation Phase I Study of AZD2281
Phase 1
Completed
- Conditions
- Advanced Solid Malignancies
- First Posted Date
- 2007-12-13
- Last Posted Date
- 2009-08-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 18
- Registration Number
- NCT00572364
- Locations
- 🇯🇵
Research Site, Tokyo, Japan
LIFE NIS, GERD-Patients - Evaluation of Burden of Disease Determined by GERD Impact Scale (GIS)
Completed
- Conditions
- GERD
- First Posted Date
- 2007-12-05
- Last Posted Date
- 2008-02-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 900
- Registration Number
- NCT00567619
- Locations
- 🇦🇹
Research Site, Vienna, Austria
German PMS Trial (AWB) to Evaluate Therapy in Reflux Disease and NSAR-Symptoms
Completed
- Conditions
- Gastroesophageal Reflux
- First Posted Date
- 2007-12-04
- Last Posted Date
- 2008-01-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 67130
- Registration Number
- NCT00567021
© Copyright 2025. All Rights Reserved by MedPath